DE69938450T2 - Verfahren zum auffinden von verbindungen, die die bindung zwischen den transkriptionsfaktoren stat1 und usf1 hemmen - Google Patents
Verfahren zum auffinden von verbindungen, die die bindung zwischen den transkriptionsfaktoren stat1 und usf1 hemmen Download PDFInfo
- Publication number
- DE69938450T2 DE69938450T2 DE69938450T DE69938450T DE69938450T2 DE 69938450 T2 DE69938450 T2 DE 69938450T2 DE 69938450 T DE69938450 T DE 69938450T DE 69938450 T DE69938450 T DE 69938450T DE 69938450 T2 DE69938450 T2 DE 69938450T2
- Authority
- DE
- Germany
- Prior art keywords
- expression
- nucleic acid
- acid sequence
- stat1
- usf1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108010044012 STAT1 Transcription Factor Proteins 0.000 title claims description 74
- 102000006381 STAT1 Transcription Factor Human genes 0.000 title claims description 74
- 101000671637 Homo sapiens Upstream stimulatory factor 1 Proteins 0.000 title claims description 58
- 102100040105 Upstream stimulatory factor 1 Human genes 0.000 title claims description 55
- 238000000034 method Methods 0.000 title claims description 34
- 150000001875 compounds Chemical class 0.000 title claims description 28
- 230000014509 gene expression Effects 0.000 claims description 89
- 150000007523 nucleic acids Chemical group 0.000 claims description 53
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 47
- 229920001184 polypeptide Polymers 0.000 claims description 47
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 46
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 46
- 102000008070 Interferon-gamma Human genes 0.000 claims description 43
- 108010074328 Interferon-gamma Proteins 0.000 claims description 43
- 102000004127 Cytokines Human genes 0.000 claims description 24
- 108090000695 Cytokines Proteins 0.000 claims description 24
- 238000005259 measurement Methods 0.000 claims description 21
- 230000004913 activation Effects 0.000 claims description 20
- 108700008625 Reporter Genes Proteins 0.000 claims description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 108020004999 messenger RNA Proteins 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
- 102000006734 Beta-Globulins Human genes 0.000 claims description 2
- 108010087504 Beta-Globulins Proteins 0.000 claims description 2
- 108090000204 Dipeptidase 1 Proteins 0.000 claims description 2
- 108060001084 Luciferase Proteins 0.000 claims description 2
- 239000005089 Luciferase Substances 0.000 claims description 2
- 102000006635 beta-lactamase Human genes 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 102100026371 MHC class II transactivator Human genes 0.000 claims 1
- 229940044627 gamma-interferon Drugs 0.000 claims 1
- 238000012797 qualification Methods 0.000 claims 1
- 230000003313 weakening effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 51
- 229960003130 interferon gamma Drugs 0.000 description 42
- 108700002010 MHC class II transactivator Proteins 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 39
- 108091035710 E-box Proteins 0.000 description 27
- 230000006698 induction Effects 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 14
- 239000000523 sample Substances 0.000 description 13
- 241001136792 Alle Species 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 10
- 101100382122 Homo sapiens CIITA gene Proteins 0.000 description 8
- 108700005092 MHC Class II Genes Proteins 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 108091054438 MHC class II family Proteins 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 6
- 230000003213 activating effect Effects 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000002079 cooperative effect Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000003298 DNA probe Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000042838 JAK family Human genes 0.000 description 2
- 108091082332 JAK family Proteins 0.000 description 2
- 108010085220 Multiprotein Complexes Proteins 0.000 description 2
- 102000007474 Multiprotein Complexes Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101000709520 Chlamydia trachomatis serovar L2 (strain 434/Bu / ATCC VR-902B) Atypical response regulator protein ChxR Proteins 0.000 description 1
- 102100026398 Cyclic AMP-responsive element-binding protein 3 Human genes 0.000 description 1
- 108700011215 E-Box Elements Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102000015789 HLA-DP Antigens Human genes 0.000 description 1
- 108010010378 HLA-DP Antigens Proteins 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 101000855520 Homo sapiens Cyclic AMP-responsive element-binding protein 3 Proteins 0.000 description 1
- 101000641077 Homo sapiens Diamine acetyltransferase 1 Proteins 0.000 description 1
- 101000713305 Homo sapiens Sodium-coupled neutral amino acid transporter 1 Proteins 0.000 description 1
- 101000837845 Homo sapiens Transcription factor E3 Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 101000671649 Homo sapiens Upstream stimulatory factor 2 Proteins 0.000 description 1
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 1
- 102000004289 Interferon regulatory factor 1 Human genes 0.000 description 1
- 108090000890 Interferon regulatory factor 1 Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010024121 Janus Kinases Proteins 0.000 description 1
- 102000015617 Janus Kinases Human genes 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101710188313 Protein U Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 102100030100 Sulfate anion transporter 1 Human genes 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000004853 Transcription Factor DP1 Human genes 0.000 description 1
- 108090001097 Transcription Factor DP1 Proteins 0.000 description 1
- 102100028507 Transcription factor E3 Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 102100040103 Upstream stimulatory factor 2 Human genes 0.000 description 1
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 1
- ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009133 cooperative interaction Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003386 epithelial cell of thymus gland Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9802025 | 1998-02-19 | ||
| FR9802025A FR2775003A1 (fr) | 1998-02-19 | 1998-02-19 | Methode de criblage de composes capables d'inhiber la fixation entre le facteur de transcription stat1 et le facteur de transcription usf1 |
| PCT/FR1999/000376 WO1999042571A1 (fr) | 1998-02-19 | 1999-02-19 | Methode de criblage de composes capables d'inhiber la fixation entre le facteur de transcription stat1 et le facteur de transcription usf1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69938450D1 DE69938450D1 (de) | 2008-05-15 |
| DE69938450T2 true DE69938450T2 (de) | 2009-05-07 |
Family
ID=9523151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69938450T Expired - Fee Related DE69938450T2 (de) | 1998-02-19 | 1999-02-19 | Verfahren zum auffinden von verbindungen, die die bindung zwischen den transkriptionsfaktoren stat1 und usf1 hemmen |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6379894B1 (https=) |
| EP (1) | EP1068310B1 (https=) |
| JP (1) | JP2002504325A (https=) |
| AU (1) | AU2431299A (https=) |
| DE (1) | DE69938450T2 (https=) |
| FR (1) | FR2775003A1 (https=) |
| WO (1) | WO1999042571A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10148886A1 (de) | 2001-10-04 | 2003-04-30 | Avontec Gmbh | Inhibition von STAT-1 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5976835A (en) * | 1992-03-19 | 1999-11-02 | The Rockefeller University | Nucleic acids encoding receptor recognition factor Stat1α and Stat1β, and methods of use thereof |
| DE69429608T2 (de) | 1993-08-26 | 2002-09-12 | Novimmune Sa, Genf/Geneve | MHC-Klasse-II Transaktivator (CIITA) und dessen Anwendungen |
| US5463023A (en) * | 1993-10-22 | 1995-10-31 | Washington University | Composition for inhibition of intracellular transcription |
| JPH09511908A (ja) * | 1994-04-14 | 1997-12-02 | リガンド・ファーマシューティカルズ・インコーポレイテッド | サイトカインに応答性のｄｎａ調節要素 |
| US5814517A (en) * | 1994-04-14 | 1998-09-29 | Ligand Pharmaceuticals, Inc. | DNA spacer regulatory elements responsive to cytokines and methods for their use |
| US5707803A (en) * | 1994-04-14 | 1998-01-13 | Ligand Pharmaceuticals, Inc. | DNA regulatory elements responsive to cytokines and methods for their use |
| AU2285995A (en) * | 1994-04-14 | 1995-11-10 | Ligand Pharmaceuticals Incorporated | Dna spacer regulatory elements responsive to cytokines and methods for their use |
| US5672473A (en) | 1994-08-24 | 1997-09-30 | President And Fellows Of Harvard College | Methods of identifying compounds useful for treating autoimmune diseases |
| US5643726A (en) * | 1994-11-10 | 1997-07-01 | The General Hospital Corporation | Methods for modulating transcription from the amyloid β-protein precursor (APP) promoter |
| US5716622A (en) * | 1995-01-06 | 1998-02-10 | The Rockefeller University | Functionally active regions of signal transducer and activators of transcription |
| US5821053A (en) * | 1995-02-10 | 1998-10-13 | Center For Blood Research, Inc. | LIL-Stat DNA binding sites and methods for identifying inhibitory binding agents |
| GB9513342D0 (en) * | 1995-06-30 | 1995-09-06 | Medical Res Council | Complexes |
| ZA97476B (en) * | 1996-01-22 | 1998-07-21 | Res Dev Foundation | Novel methods for the characterization of compounds which stimulate STF-1 expression in pancreatic islet cells. |
| FR2762327B1 (fr) * | 1997-04-22 | 1999-07-02 | Transgene Sa | Sequence d'acide nucleique de genes ciita, susceptibles d'etre impliquees dans le controle et la regulation de l'expression de genes codant pour des molecules mhc de type ii et leur utilisation, notamment comme medicament |
| US6207391B1 (en) * | 1998-03-31 | 2001-03-27 | Tularik Inc. | High-throughput screening assays for modulators of STAT4 and STAT6 activity |
| US6235873B1 (en) * | 1999-07-31 | 2001-05-22 | The Rockefeller University | Constitutively active transcription factors and their uses for identifying modulators of activity including dysproliferative cellular changes |
-
1998
- 1998-02-19 FR FR9802025A patent/FR2775003A1/fr active Pending
-
1999
- 1999-02-19 AU AU24312/99A patent/AU2431299A/en not_active Abandoned
- 1999-02-19 DE DE69938450T patent/DE69938450T2/de not_active Expired - Fee Related
- 1999-02-19 JP JP2000532511A patent/JP2002504325A/ja active Pending
- 1999-02-19 WO PCT/FR1999/000376 patent/WO1999042571A1/fr not_active Ceased
- 1999-02-19 EP EP99903787A patent/EP1068310B1/fr not_active Expired - Lifetime
-
2000
- 2000-08-18 US US09/641,999 patent/US6379894B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1068310B1 (fr) | 2008-04-02 |
| WO1999042571A1 (fr) | 1999-08-26 |
| US6379894B1 (en) | 2002-04-30 |
| JP2002504325A (ja) | 2002-02-12 |
| EP1068310A1 (fr) | 2001-01-17 |
| FR2775003A1 (fr) | 1999-08-20 |
| DE69938450D1 (de) | 2008-05-15 |
| WO1999042571A8 (fr) | 1999-11-18 |
| AU2431299A (en) | 1999-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69518558T2 (de) | Verfahren zur Diagnose von Krebs oder Präkanzerose durch Nachweis IRF-1-spezifischer RNS | |
| DE68929299T2 (de) | Multiple genomische DNA-Verstärkung zum Nachweis einer Deletion | |
| DE69430808T2 (de) | Nf-at-polypeptide und-polynukleotide | |
| Reith et al. | Cooperative binding between factors RFX and X2bp to the X and X2 boxes of MHC class II promoters. | |
| DE60123133T2 (de) | Positionsabhängige erkennung des gnn nucleotidtripletts durch zinkfinger | |
| Sellers et al. | Changing Fos oncoprotein to a Jun-independent DNA-binding protein with GCN4 dimerization specificity by swapping" leucine zippers" | |
| DE3051086C2 (https=) | ||
| DE69133135T2 (de) | Menschliche neuronale nikotin-acetylcholin-rezeptor-verbindungen und methoden ihres einsatzes | |
| DE69321580T2 (de) | Car-rezeptoren und verwandte moleküle und entsprechende methoden | |
| DE69231903T2 (de) | Mit isoliertem empfindlichem x-syndrom verbundene dns-sequenzen | |
| DE60026150T2 (de) | Diagnostika und therapeutika für osteoporose | |
| DE19957065B4 (de) | Screening-Verfahren für Arzneistoffe | |
| DE69938450T2 (de) | Verfahren zum auffinden von verbindungen, die die bindung zwischen den transkriptionsfaktoren stat1 und usf1 hemmen | |
| DE60036750T2 (de) | Verfahren zur Abschätzung der Sensitivität für Osteoporose-Medikamente | |
| DE69527073T2 (de) | Verfahren zur identifizierung von verbindungen, die zur behandlung von autoimmunkrankheiten verwendbar sind | |
| DE3855634T2 (de) | Innerhalb des alpha-Locus gelegenes T-Zell-Rezeptor-Gen und DNA-Konstruktionen | |
| DE602005004026T2 (de) | Einen transkriptionsfaktor kodierendes humanes prädispositionsgen für autismus sowie dessen verwendungen | |
| DE69429608T2 (de) | MHC-Klasse-II Transaktivator (CIITA) und dessen Anwendungen | |
| DE69809930T2 (de) | Isolierung und verwendung von nukleinsäuremolekülen, welche für mitglieder der ssx-familie kodieren | |
| DE112004002318T5 (de) | Transkriptionsregulatoren und Verfahren dazu | |
| Chu et al. | Mutation of a neutral amino acid in the transit peptide of rat mitochondrial malate dehydrogenase abolishes binding and import. | |
| EP1282827B1 (de) | Verfahren zum selektieren von inhibitoren für enzyme | |
| EP0864656A2 (de) | In vitro Transkriptionsverfahren zum Screening von Naturstoffen und anderen chemischen Substanzen | |
| DE60316161T2 (de) | Neue kcnq-polypeptide und deren verwendung bei der diagnose von geisteskrankheiten | |
| DE69838565T2 (de) | Nukleinsäuren von CIITA Genen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |